Business Wire

Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study of Abenacianine (VGT-309) for Tumor Visualization During Lung Cancer Surgery

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3 ...
Financial Post

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

Researchers at six sites in the U.S. and Australia will investigate the agent’s ability to help surgeons see tumors in real time during minimally invasive and robotic-assisted surgical procedures ...
Business Wire

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the company has enrolled the first patients in a Phase ...
Morningstar

Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study of Abenacianine (VGT-309) for Tumor Visualization During Lung Cancer Surgery

Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3, multi-center, pivotal study ...